MedTech Innovator VANTAGE Accelerator

mti vantage logo

MedTech Innovator Accelerator

MedTech Innovator Vantage Accelerator program as part of the core MedTech Innovator annual cohort will select up to 10 companies annually to participate in the four-month program.

Applying to MedTech Innovator Accelerator

All early- to mid-stage medical device and diagnostic companies are encouraged to apply to the MedTech Innovator Accelerator program. Vantage aims to build a robust healthcare infrastructure with the technologies it supports to effectively prevent, detect, and respond to public health emergencies.

Oct – Dec 2026
Application Period Virtual
Mar – April 2027

Pitch Events
In-person & Virtual

Jun 2027

Innovator Summit
In-person

Jun – Oct 2027

Accelerator Program
Virtual

Oct & Nov 2027

Finals Competitions
In-person

Preferably, applicants will have a prototype and some proof-of-concept evidence, along with sufficient funding or runway remaining to execute during the program. Founders who have developed an applicable technology but have not yet formed a company may still apply; however, they must be incorporated before the accelerator program begins.

Companies accepted to the program must commit a (co-)founder, CEO, or appropriate senior member of their leadership team to attend the June Innovator Summit, participate in the virtual accelerator program through October, and be present for the Showcase and Finals at The MedTech Conference in October.

Applying to MedTech Innovator Accelerator

All early- to mid-stage medical device and diagnostic companies are encouraged to apply to the MedTech Innovator Accelerator program. Vantage aims to build a robust healthcare infrastructure with the technologies it supports to effectively prevent, detect, and respond to public health emergencies.

Preferably, applicants will have a prototype and some proof-of-concept evidence, along with sufficient funding or runway remaining to execute during the program. Founders who have developed an applicable technology but have not yet formed a company may still apply; however, they must be incorporated before the accelerator program begins.

Companies accepted to the program must commit a (co-)founder, CEO, or appropriate senior member of their leadership team to attend the June Innovator Summit, participate in the virtual accelerator program through October, and be present for the Showcase and Finals at The MedTech Conference in October.

The MedTech Innovator Vantage Experience for Diagnostics and Medical Device Startups

Mentorship

In-depth, customized mentorship from senior industry leaders featuring pitch coaching, goal setting, value proposition development, and corporate mentorship.​

Educational Curriculum

A bespoke educational curriculum, including cohort-driven webinars, open office hours, and hands-on workshops.

Community

Engagement with a robust ecosystem of peers, alumni, and strategic subject matter experts.

Recognition & Visibility

Recognition and visibility to potential partners, investors, and suppliers.

Resources & Funding

Access to unparalleled resource opportunities through networking, leading industry events, and MTI's ecosystem.

Backed by MedTech Innovator, the World’s Largest Accelerator for Medical Technology

Since 2012, MedTech Innovator (“MTI”) has grown significantly, establishing a major presence in the medical device industry. MTI has built a proven track record of identifying and transitioning healthcare products of all stages of technology readiness to follow-on investment and successful commercialization. MedTech Innovator has been a catalyst for groundbreaking healthcare solutions, reviewing 13,000 applicants and fostering the growth of 744 companies that have collectively raised over $12 billion in follow-on funding and introduced more than 350 products to the market, transforming the lives of millions.

Who Should Apply?

MedTech Innovator supports a wide range of healthcare technologies, including medical devices, diagnostics, and digital health solutions. Company stage ranges from Pre-Seed to Series C, and technology readiness varies from concept stage to FDA-approved and on the market. Our tailored curriculum and mentorship offer value across the startup lifecycle.

The Vantage Accelerator program focuses on advancing technologies for the detection, treatment, diagnosis, and overall response to pathogens and the consequences of biological threats in BARDA’s mission space. Areas of interest include, but are not limited to:

  • Continuous patient monitoring platforms that integrate advanced sensors (e.g. for monitoring of blood pressure) and health data to improve patient outcomes; radiation injury cases such as acute radiation syndrome are of particular interest.
  • High sensitivity point-of-care multiplexed rapid tests capable of detecting analytes at femtomolar concentrations. Applications focused on detection of Botulinum toxin, distinguishing all 8 serotypes, are of particular interest.
  • Low-cost deployable diagnostic tools and devices suited for rural, resource-limited, or point-of-need settings
  • Diagnostic tools for rapid triage with particular interest in rapid, low-throughput next-generation sequencing (NGS) platforms that allow pathogen identification/investigation with 1–10 samples/run

For more information on technologies suitable for MedTech Innovator, please reference our MedTech Innovator Strategic Interest Areas page. For more information on BARDA areas of interest, please reference DRIVe’s webpage and BARDA’s target product profiles.

Who Should Apply?

MedTech Innovator supports a wide range of healthcare technologies, including medical devices, diagnostics, and digital health solutions. Company stage ranges from Pre-Seed to Series C, and technology readiness varies from concept stage to FDA-approved and on the market. Our tailored curriculum and mentorship offer value across the startup lifecycle.

The Vantage Accelerator program focuses on advancing technologies for the detection, treatment, diagnosis, and overall response to pathogens and the consequences of biological threats in BARDA’s mission space. Areas of interest include, but are not limited to:

  • Point-of-Care and At-Home Molecular Diagnostics with high sensitivity, high specificity, and low cost to enable rapid detection of emerging infectious disease and biological threats outside traditional lab settings
  • Pathogen-Agnostic Detection Platforms that identify novel or unknown biological threats without requiring prior knowledge of the causative agent
  • Alternative Sampling and Detection Approaches (e.g., breath, saliva, wearable biosensors) that simplify and improve the user experience of sample collection and analysis
  • Exposure Surveillance and Triage Platforms to screen for, detect, track, and prioritize patients exposed to biothreats
  • Continuous Patient Monitoring Platforms that integrate advanced sensors and health data to improve patient outcomes
  • Low-Cost, Deployable Diagnostic and Medical Devices suited for rural, resource-limited, or point-of-need field settings
  • Medical Devices for Casualty Care and Emergency Response that improve clinical decision-making and coordination of care following mass-casualty or CBRN events

For more information on technologies suitable for MedTech Innovator, please reference our MedTech Innovator Strategic Interest Areas page. For more information on BARDA areas of interest, please reference DRIVe’s webpage and BARDA’s target product profiles.

mti vantage logo
For additional information and questions, please contact
vantage@medtechinnovator.org